CYTOKINETICS, INCORPORATED (CYTK) Operating Margin
- Operating margin · 12 months: Value -1046.12%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1046.12% | Operating income / revenue. Period ending 2026-06-30. $-707.91M ÷ $67.67M × 100 ≈ -1046.12% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -707.91M USD | Operating Income (Loss) |
| Revenue | 67.67M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 400.96M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-707.91M | $67.67M | (m) | $400.96M | (m) | -1046.12% |
| 2026-03-31 | $-640.25M | $105.81M | (m) | $413.29M | (m) | -605.06% |
| 2025-12-31 | $-612.26M | $88.04M | (m) | $416.03M | (m) | -695.44% |
| 2025-09-30 | $-572.93M | $87.21M | (m) | $405.26M | (m) | -656.95% |
| 2025-06-30 | $-546.98M | $85.74M | (m) | $390.64M | (m) | -637.96% |
| 2025-03-31 | $-565.64M | $19.22M | (m) | $357.68M | (m) | -2943.30% |
| 2024-12-31 | $-536.25M | $18.47M | (m) | $339.41M | (m) | -2902.72% |
| 2024-09-30 | $-524.63M | $3.22M | (m) | $330.75M | (m) | -16297.79% |
| 2024-06-30 | $-506.09M | $3.13M | (m) | $328.68M | (m) | -16148.37% |
| 2024-03-31 | $-497.97M | $3.75M | (m) | $332.27M | (m) | -13272.04% |
| 2023-12-31 | $-496.20M | $7.53M | (m) | $330.12M | (m) | -6589.71% |
| 2023-09-30 | $-495.82M | $7.82M | (m) | $320.17M | (m) | -6344.43% |
| 2023-06-30 | $-481.99M | $9.95M | (m) | $300.37M | (m) | -4843.18% |
| 2023-03-31 | $-370.82M | $98.05M | (m) | $274.30M | (m) | -378.18% |
| 2022-12-31 | $-324.20M | $94.59M | (m) | $240.81M | (m) | -342.75% |
| 2022-09-30 | $-218.88M | $148.23M | (m) | $209.29M | (m) | -147.66% |
| 2022-06-30 | $-179.64M | $151.15M | (m) | $195.00M | (m) | -118.84% |
| 2022-03-31 | $-223.56M | $65.03M | (m) | $174.31M | (m) | -343.79% |
| 2021-12-31 | $-186.31M | $70.43M | (m) | $159.94M | (m) | -264.54% |
| 2021-09-30 | $-201.02M | $21.55M | (m) | $145.66M | (m) | -932.79% |
| 2021-06-30 | $-126.63M | $57.80M | (m) | $121.43M | (m) | -219.08% |
| 2021-03-31 | $-104.19M | $58.55M | (m) | $106.77M | (m) | -177.95% |
| 2020-12-31 | $-93.94M | $55.83M | (m) | $96.95M | (m) | -168.27% |
| 2020-09-30 | $-81.24M | $54.32M | (m) | $86.06M | (m) | -149.57% |
| 2020-06-30 | $-110.35M | $18.68M | (m) | $82.09M | (m) | -590.60% |
| 2020-03-31 | $-104.71M | $22.23M | (m) | $84.32M | (m) | -471.06% |
| 2019-12-31 | $-98.87M | $26.87M | (m) | $86.13M | (m) | -367.97% |
| 2019-09-30 | $-96.62M | $31.03M | (m) | $91.07M | (m) | -311.34% |
| 2019-06-30 | $-90.61M | $35.62M | (m) | $92.98M | (m) | -254.38% |
| 2019-03-31 | $-87.30M | $34.70M | (m) | $90.55M | (m) | -251.62% |
| 2018-12-31 | $-88.92M | $31.50M | (m) | $89.14M | (m) | -282.26% |
| 2018-09-30 | $-103.98M | $22.11M | (m) | $92.11M | (m) | -470.39% |
| 2018-06-30 | $-114.50M | $17.64M | (m) | $94.92M | (m) | -648.88% |
| 2018-03-31 | $-116.28M | $14.48M | (m) | $93.14M | (m) | -802.84% |
| 2017-12-31 | $-113.40M | $13.37M | (m) | $90.30M | (m) | -848.26% |
| 2017-09-30 | $-69.18M | $46.52M | (m) | $82.82M | (m) | -148.70% |
| 2017-06-30 | $-6.79M | $99.39M | (m) | $75.74M | (m) | -6.83% |
| 2017-03-31 | $7.39M | $102.14M | (m) | $65.65M | (m) | 7.24% |
| 2016-12-31 | $18.69M | $106.41M | (m) | $59.90M | (m) | 17.56% |
| 2016-09-30 | $503.00K | $83.03M | (m) | $55.84M | (m) | 0.61% |
| 2016-06-30 | $-40.87M | $31.92M | (m) | $48.06M | (m) | -128.04% |
| 2016-03-31 | $-40.45M | $32.66M | (m) | $50.98M | (m) | -123.84% |
| 2015-12-31 | $-37.41M | $28.66M | (m) | $46.40M | (m) | -130.53% |
| 2015-09-30 | $-19.96M | $40.66M | (m) | $41.93M | (m) | -49.10% |
| 2015-06-30 | $-17.07M | $42.13M | (m) | $41.79M | (m) | -40.53% |
| 2015-03-31 | $-14.89M | $43.38M | (m) | $40.89M | (m) | -34.34% |
| 2014-12-31 | $-14.75M | $46.94M | (m) | $44.43M | (m) | -31.43% |
| 2014-09-30 | $-16.74M | $49.53M | (m) | $49.47M | (m) | -33.80% |
| 2014-06-30 | $-23.36M | $44.59M | (m) | $51.50M | (m) | -52.39% |
| 2014-03-31 | $-30.02M | $37.81M | (m) | $52.11M | (m) | -79.40% |
| 2013-12-31 | $-33.89M | $30.65M | (m) | $49.45M | (m) | -110.59% |
| 2013-09-30 | $-51.81M | $8.48M | (m) | $45.48M | (m) | -610.81% |
| 2013-06-30 | $-49.28M | $5.73M | (m) | $40.84M | (m) | -860.27% |
| 2013-03-31 | $-43.16M | $6.56M | (m) | $36.73M | (m) | -657.99% |
| 2012-12-31 | $-40.46M | $7.56M | (m) | $35.64M | (m) | -535.22% |
| 2012-09-30 | $-40.87M | $6.13M | (m) | $34.38M | (m) | -666.42% |
| 2012-06-30 | $-41.46M | $5.84M | (m) | $34.48M | (m) | -709.46% |
| 2012-03-31 | $-46.15M | $5.06M | (m) | $36.75M | (m) | -912.64% |
| 2011-12-31 | $-47.96M | $4.00M | (m) | $37.18M | (m) | -1199.10% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-49.63M | $2.58M | (m) | $38.01M | (m) | -1926.08% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $26.09M | $81.54M | (m) | $39.84M | (m) | 32.00% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |